For UK pharmaceutical and life sciences leaders
When the clawback rate shifts, your UK P&L shifts with it
Voluntary scheme clawback percentages change year on year, yet most commercial teams are still modelling obligations on last year's figure. On significant UK revenue, even a small modelling error becomes a large P&L error.
Two minutes. Solva follows up with specific scheme modelling and forecasting options.
VPAS clawback rates reached 26.5% in 2023 - the highest since the scheme began, making UK profitability modelling critical. (ABPI, 2024)
Frequently asked questions
Why does this problem persist?
The Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) and its successor create significant and unpredictable clawback obligations for branded medicines companies. Most UK commercial teams don't model these accurately.
What is the cost of leaving it unaddressed?
A company with £100m UK revenue facing a 26.5% clawback has £26.5m in obligations. A 1% error in clawback modelling is a £1m P&L error.
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.